Baptist Health | Strategic Alliance Partners

This OPC interview discusses practice-changing updates from ASCO and EHA, including advances in bispecific antibodies, breast cancer treatment strategies, and multiple myeloma sequencing considerations.

Experts discuss real-world BTCE challenges, toxicity monitoring, and evolving pharmacy practice.

Practical insights for navigating rare, high-stakes toxicities.

New data, emerging targets, and evolving ADC use are reshaping second-line decisions.

Key risks, overlooked toxicities, and real-world monitoring strategies for bispecific T-cell engagers.

Antibody-drug conjugates have revolutionized metastatic breast cancer treatment and classification.

Colorectal cancer cases are on the rise—here is everything you need to know as an oncology pharmacist.

Megan May, PharmD, BCOP, FHOPA, FAPO, discusses lurbinectedin and tarlatamab and what ongoing research in the small cell lung cancer (SCLC) space entails.

After decades without improvements, an expert with Baptist Health described the small cell lung cancer (SCLC) space as “exciting” following multiple innovations in the past few years.

Analyzing consolidation of 8 drug pump libraries into 1 IV infusion library in a 9-hospital system: from standardization to implementation.

Pharmacists should continue to monitor payer policy changes and reimbursement rates and improve understanding of electronic order entry.

How can a multisite health system create a system pharmacy and therapeutics committee (P & T) that is meaningful for its acute care hospitals and infusion centers?